NEW YORK (GenomeWeb) – Epigenomics today reported a 55 percent drop in its 2017 revenues, a decline the company attributed in part to fewer orders for its Epi proColon colorectal cancer test.

For the year ended Dec. 31, Epigenomics posted revenues of €1.9 million ($2.3 million) from €4.2 million the year before. Revenues of about €1.3 million were generated through licensing income, while product sales for the year were approximately €500,000, the firm said.